Short-term, severe calorie restriction (fasting-mimicking diet) was found to be safe, and resulted in biological effects in the body that may be helpful in cancer treatment, according to the report of a clinical trial published in Cancer Discovery, a journal of the American Association for Cancer Research.
“Our results from a first-in-human clinical trial showed that a scheme of severe short-term calorie restriction was safe and biologically active in patients, and that its activity likely involved the activation of immune responses,” said Claudio Vernieri, MD, PhD, a medical oncologist at the National Cancer Institute (INT) in Milan, Italy. “Since calorie restriction is a safe, inexpensive, and potentially effective approach that could be easily combined with standard antineoplastic therapies, we think these findings might have relevant implications for cancer therapy.”
Evaluating the fasting-mimicking diet in cancer patients
101 patients with various forms of cancer who were being treated with different standard anticancer therapies were involved in this study to assess the safety, feasibility, and metabolic effects of the fasting-mimicking diet (FMD) in cancer patients. The FMD regimen consisted of a five-day, low-carbohydrate, low-protein, plant-derived diet, which provided up to 600 Kcal on day 1 and up to 300 Kcal on days 2, 3, 4, and 5, for a total amount of up to 1,800 Kcal in five days. The cycle was repeated every three or four weeks for up to a maximum of eight consecutive cycles.
Results
According to the researchers, the results showed that the FMD regimen was safe, feasible, and well-tolerated by the majority of patients. The incidence of severe FMD-related adverse events was 12.9 percent, the most common being fatigue, which was rarely severe. The biological impacts included a decrease in blood glucose, insulin, and growth factor, a reduction in peripheral blood immunosuppressive cells, and enhanced intratumor T-cell infiltration in cancer patients receiving standard-of-care therapy.
”The metabolic modifications observed in our patients recapitulate those induced by calorie restriction in preclinical models, in which they are associated with potent antitumor effects,” said Vernieri.
Calorie restriction was followed by a refeeding period of 16 to 23 days, during which patients were not subjected to specific dietary restrictions but were recommended to adhere to international guidelines for a healthy diet and lifestyle. Any loss of body weight that occurred during the five days of severe calorie restriction was reversible in most of the patients during this refeeding period.
“This is an especially important finding, because it excludes the risk that patients might undergo progressive weight loss and/or malnourishment, which are associated with reduced efficacy of anticancer therapies and reduced survival,” commented co Filippo de Braud, MD, director of oncology and hematology at INT and professor of medical oncology at the University of Milan.
Evaluating effects on immune responses
Next, the team evaluated the effects of the FMD on patient immune responses. An analysis conducted on 38 patients at the end of a five-day FMD cycle revealed a significant decrease in circulating immunosuppressive cells and an increase in activated T cells. These effects occurred independently of concomitant antitumor therapies and were also observed in a small group of healthy volunteers.
Assessing changes in tumors
Assessing the changes at the tumor level was done by analyzing the interim results of another ongoing trial, the DigesT, testing a five-day FMD cycle before surgery in early-stage breast cancer and melanoma patients. Results from this analysis revealed a significant increase in tumor-infiltrating T cells and other changes, suggesting a desirable switch toward an antitumor immune microenvironment following FMD.
“Severe calorie restriction generated a metabolic ‘shock’ that activated several populations of immune cells that could boost the antitumor activity of standard antineoplastic treatments,” said coauthor Licia Rivoltini, MD, head of the Immunotherapy of Human Tumors Unit at INT.
As with anything you read on the internet, this article should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine. WHN does not agree or disagree with any of the materials posted. This article is not intended to provide a medical diagnosis, recommendation, treatment, or endorsement. Additionally, it is not intended to malign any religion, ethnic group, club, organization, company, individual, or anyone or anything. These statements have not been evaluated by the Food and Drug Administration.
Content may be edited for style and length.
References/Sources/Materials provided by:
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(24)00270-5
https://clinicaltrials.gov/ct2/show/NCT03340935
https://cancerdiscovery.aacrjournals.org
https://worldhealth.net/news/will-a-healthy-diet-help-reduce-the-risk-of-cancer/
https://worldhealth.net/news/healthy-diet-doesnt-guarantee-being-cancer-free/
